Literature DB >> 14609486

The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses.

Dana P Ascherman1.   

Abstract

Polymyositis represents an autoimmune disease in which T cells mediate destruction of muscle cells. Although the precise trigger(s) for this process remain unknown, distinct clinical subsets exist that are characterized by antibodies directed against specific nuclear and cytoplasmic antigens including Jo-1 (histidyl-transfer RNA synthetase). Coupled with a range of genetic and histomorphologic data, the stereotypical serologic response suggests that antigen-specific T cells directed against Jo-1 can promote T cell-mediated cytolysis of muscle cells as well as anti-Jo-1 antibody formation in selected patients with polymyositis. Beyond a previously developed animal model that has demonstrated the capacity of Jo-1 to promote humoral and cell-mediated immune responses leading to myositis, recent studies have revealed the existence of Jo-1-specific T cells in the peripheral blood of patients with Jo-1 antibody-positive polymyositis. Even more striking, investigators have discovered that Jo-1 can serve as a chemokine for immature dendritic cells and T lymphocytes. Collectively, these findings suggest a mechanism by which Jo-1 can bridge the innate and adaptive immune responses, leading to the breakdown of tolerance and autoimmune destruction of muscle.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14609486     DOI: 10.1007/s11926-003-0052-2

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  40 in total

1.  Analysis of soluble and cell surface factors regulating anti-DNA topoisomerase I autoantibody production demonstrates synergy between Th1 and Th2 autoreactive T cells.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Immunol       Date:  2000-06-15       Impact factor: 5.422

2.  Quantitative and functional analysis of PDC-E2-specific autoreactive cytotoxic T lymphocytes in primary biliary cirrhosis.

Authors:  Hiroto Kita; Shuji Matsumura; Xiao-Song He; Aftab A Ansari; Zhe-Xiong Lian; Judy Van de Water; Ross L Coppel; Marshall M Kaplan; M Eric Gershwin
Journal:  J Clin Invest       Date:  2002-05       Impact factor: 14.808

3.  Two distinct cytokines released from a human aminoacyl-tRNA synthetase.

Authors:  K Wakasugi; P Schimmel
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

Review 4.  Posttranslational protein modifications, apoptosis, and the bypass of tolerance to autoantigens.

Authors:  P J Utz; P Anderson
Journal:  Arthritis Rheum       Date:  1998-07

Review 5.  Autoreactive responses to pyruvate dehydrogenase complex in the pathogenesis of primary biliary cirrhosis.

Authors:  S J Yeaman; J A Kirby; D E Jones
Journal:  Immunol Rev       Date:  2000-04       Impact factor: 12.988

6.  Cytotoxic mechanisms in inflammatory myopathies. Co-expression of Fas and protective Bcl-2 in muscle fibres and inflammatory cells.

Authors:  L Behrens; A Bender; M A Johnson; R Hohlfeld
Journal:  Brain       Date:  1997-06       Impact factor: 13.501

7.  Expression of tumor necrosis factor-alpha in muscles of polymyositis.

Authors:  M Tateyama; I Nagano; M Yoshioka; K Chida; S Nakamura; Y Itoyama
Journal:  J Neurol Sci       Date:  1997-02-27       Impact factor: 3.181

8.  T cell proliferative response induced by DNA topoisomerase I in patients with systemic sclerosis and healthy donors.

Authors:  M Kuwana; T A Medsger; T M Wright
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

9.  Genomic organization, transcriptional mapping, and evolutionary implications of the human bi-directional histidyl-tRNA synthetase locus (HARS/HARSL).

Authors:  Terrance P O'Hanlon; Frederick W Miller
Journal:  Biochem Biophys Res Commun       Date:  2002-06-14       Impact factor: 3.575

10.  T cell receptor repertoire in polymyositis: clonal expansion of autoaggressive CD8+ T cells.

Authors:  A Bender; N Ernst; A Iglesias; K Dornmair; H Wekerle; R Hohlfeld
Journal:  J Exp Med       Date:  1995-05-01       Impact factor: 14.307

View more
  13 in total

Review 1.  Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome.

Authors:  Dana P Ascherman
Journal:  Curr Rheumatol Rep       Date:  2015-09       Impact factor: 4.592

2.  Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis.

Authors:  Makoto Soejima; Eun Ha Kang; Xinyan Gu; Yasuhiro Katsumata; Paula R Clemens; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2011-02

3.  Plasmonic substrates for multiplexed protein microarrays with femtomolar sensitivity and broad dynamic range.

Authors:  Scott M Tabakman; Lana Lau; Joshua T Robinson; Jordan Price; Sarah P Sherlock; Hailiang Wang; Bo Zhang; Zhuo Chen; Stephanie Tangsombatvisit; Justin A Jarrell; Paul J Utz; Hongjie Dai
Journal:  Nat Commun       Date:  2011-09-13       Impact factor: 14.919

Review 4.  Antisynthetase syndrome.

Authors:  Elena Katzap; Maria-Louise Barilla-LaBarca; Galina Marder
Journal:  Curr Rheumatol Rep       Date:  2011-06       Impact factor: 4.592

5.  Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.

Authors:  Rohit Aggarwal; Andriy Bandos; Ann M Reed; Dana P Ascherman; Richard J Barohn; Brian M Feldman; Frederick W Miller; Lisa G Rider; Michael O Harris-Love; Marc C Levesque; Chester V Oddis
Journal:  Arthritis Rheumatol       Date:  2014-03       Impact factor: 10.995

6.  The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis.

Authors:  Hector Chinoy; Noreen Fertig; Chester V Oddis; William E R Ollier; Robert G Cooper
Journal:  Ann Rheum Dis       Date:  2007-03-28       Impact factor: 19.103

7.  Sensitive and robust luminescent profiling of anti-La and other autoantibodies in Sjogren's syndrome.

Authors:  Peter D Burbelo; Hannah P Leahy; Alexandra T Issa; Sandra Groot; James N Baraniuk; Nikolay P Nikolov; Gabor G Illei; Michael J Iadarola
Journal:  Autoimmunity       Date:  2009-09       Impact factor: 2.815

Review 8.  Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology.

Authors:  V Madan; H Chinoy; C E M Griffiths; R G Cooper
Journal:  Clin Exp Dermatol       Date:  2009-07       Impact factor: 3.470

9.  Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.

Authors:  Rohit Aggarwal; Chester V Oddis; Danielle Goudeau; Diane Koontz; Zengbiao Qi; Ann M Reed; Dana P Ascherman; Marc C Levesque
Journal:  Rheumatology (Oxford)       Date:  2016-02-16       Impact factor: 7.580

Review 10.  Rituximab in refractory idiopathic inflammatory myopathies and antisynthetase syndrome: personal experience and review of the literature.

Authors:  Linda Nalotto; Luca Iaccarino; Margherita Zen; Mariele Gatto; Elisabetta Borella; Marta Domenighetti; Leonardo Punzi; Andrea Doria
Journal:  Immunol Res       Date:  2013-07       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.